Advertisements

Maxifort-Zimax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Maxifort-Zimax

Quick Facts

Property Description
Active ingredient Sildenafil (as Citrate salt)
Form Film-coated tablet
Pharmacological class Phosphodiesterase Type 5 (PDE5) Inhibitor
General purpose Enhances localized vascular flow
Origin Synthetic compound

What Type of Medicine is Maxifort-Zimax?

Maxifort-Zimax is a synthetic pharmaceutical product whose fundamental active component is the molecule Sildenafil, which is administered as a single-ingredient product via the oral route. This medicine belongs to the Phosphodiesterase Type 5 (PDE5) Inhibitor pharmacological group, a class of compounds clinically recognized for their effect on blood vessel regulation. As a branded preparation, Maxifort-Zimax is typically associated with manufacturers focusing on specific regional markets, providing a defined delivery system for Sildenafil.

Composition and Pharmaceutical Form

The active ingredient is Sildenafil (chemically identified as Sildenafil Citrate), a molecule that is entirely synthetic in origin. It is consistently provided in the dosage form of a film-coated tablet, ensuring stable and precise delivery. This oral form guarantees a reliable dose of the active compound. The tablet composition includes Sildenafil alongside standard solid pharmaceutical excipients, which are the inactive materials necessary for the formulation's structure and stability.

Primary Action and General Therapeutic Purpose

The general therapeutic purpose of this PDE5 inhibitor is to enhance the body’s intrinsic mechanism for achieving vasodilation (vessel widening) in specific regions. This action is achieved by inhibiting the PDE5 enzyme, which allows the natural signaling molecule, cGMP, to accumulate. This targeted mechanism results in smooth muscle relaxation and enhanced local blood flow. This principle reflects the established pharmacology of PDE5 inhibitors and their role in supporting sustained blood circulation.

Regulatory References

  1. Sildenafil - StatPearls - NCBI Bookshelf - NIH
Advertisements

What side effects are possible with Maxifort-Zimax?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics of Sildenafil, the active ingredient in Maxifort-Zimax, based strictly on government-approved prescribing information. The safety profile is defined by frequency classifications, ranging from very common to rare.

Frequency-Classified Adverse Reactions

The most frequently documented effects relate to the drug's fundamental mechanism of enhancing vascular flow:

  • Very Common (ge 1 in 10 users): Headache and Flushing.
  • Common (ge 1 in 100 to < 1 in 10 users): Dizziness, Vision disturbances (including blurred vision and color tinge to vision), Dyspepsia (indigestion), Nasal congestion, and Hypotension (low blood pressure).

Less common effects include cardiac disorders such as Palpitations and Tachycardia (increased heart rate), as well as Rash and Hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

Certain reactions are documented as rare but medically significant in regulatory labeling:

  • Rare Adverse Reactions include Priapism (a prolonged erection lasting more than four hours) and Non-arteritic anterior ischemic optic neuropathy (NAION), which can potentially result in sudden vision loss. Sudden decrease or loss of hearing has also been documented post-marketing.

The most stringent safety restriction is the absolute contraindication with any form of organic nitrate or nitric oxide donor. The concurrent use of Sildenafil with these compounds can result in severe, life-threatening hypotension. Furthermore, use is contraindicated in patients with a recent history of stroke or myocardial infarction, and in those with known hereditary degenerative retinal disorders. Safety notes also indicate reduced clearance in patients with severe hepatic or renal impairment.

Advertisements

Overdose and Emergency Response

Maxifort-Zimax Overdose and when to seek help

The official regulatory profile states that overdose of Sildenafil (the active component of Maxifort-Zimax) is primarily associated with an increased incidence and severity of known adverse reactions [FDA Prescribing Information].

Feature Official Regulatory Statement
Documented Manifestations Increased severity of symptoms such as headache, flushing, dyspepsia, and visual disturbances; physiological findings may include hypotension (decreased blood pressure).
Serious Outcomes Risk of priapism (an erection lasting more than four hours), which may lead to penile tissue damage and permanent loss of potency; sudden visual loss or hearing loss.
Population-Specific Note Patients with severe hepatic or severe renal impairment may have increased systemic exposure, potentially raising the risk of adverse effects.

When to Seek Immediate Medical Help

The most critical emergency action explicitly mandated by regulators is to seek immediate medical attention for an erection that persists for more than four hours [NIH MedlinePlus Drug Information]. Individuals must also stop taking the medicine immediately and consult a physician if they experience a sudden decrease or loss of vision or hearing. Management is limited to symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known.

Advertisements

Therapeutic Uses of Maxifort-Zimax

Maxifort-Zimax (Sildenafil) is commonly used across two distinct therapeutic domains, offering supportive relief for conditions that may present with symptoms related to inadequate vascular response and the resulting functional impairment. This dual therapeutic scope covers both sexual and cardiopulmonary health.

The medication is relevant for managing erectile dysfunction (ED) in adult men and for the chronic treatment of Pulmonary Arterial Hypertension (PAH). In these clinical scenarios, the drug is applied when symptoms create noticeable physiological strain, whether stemming from the inability to achieve adequate penile rigidity or from reduced exercise tolerance and exertion-related shortness of breath. The therapeutic goal supports the patient during these difficult episodes, contributing to easing distress and the overall symptom burden.

“The treatment may provide supportive relief when symptoms interfere with routine activities, supports general well-being during symptomatic phases.”

Quick Fact: Relief for Impaired Vascular Function
Symptom categories Impaired localized blood flow, reduced functional capacity
Conditions Erectile dysfunction, Pulmonary Arterial Hypertension
Patient benefit Assists with maintaining functional stability and contributes to improved comfort during symptomatic periods

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Population Eligibility: Contraindications and Restrictions

Maxifort-Zimax (Sildenafil) is approved for adult men with erectile dysfunction and for adults (men and women) with pulmonary arterial hypertension (PAH). Use for PAH is also established for pediatric patients (aged 1 year and older) in some regulatory regions, but the medicine is not indicated for the treatment of erectile dysfunction in children.


Absolute Contraindications

Official regulatory labels define several groups for whom use is strictly prohibited:

  • Patients with known hypersensitivity to Sildenafil or any tablet component.
  • Patients using any form of organic nitrate or nitric oxide donors.
  • Patients using guanylate cyclase stimulators (e.g., riociguat).
  • Patients with a history of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION).
  • Patients with severe hepatic impairment, severe hypotension (BP <90/50 mmHg), or a recent history of stroke or myocardial infarction.

Conditional Use and Restrictions

Use is restricted or requires caution for patients with severe renal impairment or mild to moderate hepatic impairment. It is also restricted for those with conditions predisposing them to priapism (e.g., sickle cell anaemia) or those with anatomical deformation of the penis.

Advertisements

What should I know about interactions with other medicines?

The interaction profile for Maxifort-Zimax (Sildenafil) is based on official regulatory statements, focusing on high-risk prohibitions and conditions that alter the drug's exposure.

Prohibited Combinations

Co-administration with organic nitrates (such as nitroglycerin) and the guanylate cyclase stimulator riociguat is strictly contraindicated. This prohibition stems from a severe pharmacodynamic interaction that potentiates vasodilatory effects, leading to a significant and potentially critical drop in systemic blood pressure.

Exposure-Altering Interactions

Sildenafil is cleared predominantly by the hepatic enzyme CYP3A4. Potent CYP3A4 inhibitors (including ritonavir and saquinavir) significantly increase Sildenafil plasma exposure (AUC and Cmax), as documented in the label. This risk necessitates a mandatory timing restriction; for example, the maximum single dose must not be exceeded within a 48-hour period when used with ritonavir. Conversely, CYP3A4 inducers (such as rifampicin) are expected to decrease Sildenafil plasma levels.

Additive and Other Effects

Pharmacodynamic interactions are also documented with alpha-blockers and other antihypertensive agents, which may lead to additive blood pressure lowering and the risk of symptomatic hypotension. The official information further notes that ingestion with a high-fat meal reduces the maximum plasma concentration and delays absorption time, while the use of grapefruit juice or alcohol is also noted in regulatory interaction sections.

Advertisements

Mechanism of Action

How Maxifort-Zimax Works

Maxifort-Zimax (Sildenafil) works by intervening in a natural biological cascade that regulates blood vessel diameter. The mechanism relies entirely on targeted enzyme inhibition to amplify a local chemical signal, leading to a specific physiological consequence.


Targeted Inhibition of the PDE5 Enzyme

The primary mechanism involves the competitive inhibition of the Phosphodiesterase Type 5 (PDE5) enzyme. This inhibition prevents the rapid breakdown of cyclic Guanosine Monophosphate (cGMP), a key second messenger molecule. By sustaining high cGMP levels, the drug amplifies the natural chemical signal for smooth muscle relaxation. This process sustains the signaling intensity of the cGMP second messenger system.


Potentiation of Localized Vasodilation

The resulting accumulation of cGMP enhances the chemical sequence that leads to the physiological outcome of vasodilation (vessel widening). This smooth muscle relaxation reduces local vascular resistance, which is the primary physiological consequence resulting from the mechanism. The action is signal-dependent, meaning it only potentiates the pathway in tissues where the necessary upstream signal (Nitric Oxide) has been released.

Advertisements

Dosage and Administration Information

How to Use Maxifort-Zimax: Administration Guidelines

Maxifort-Zimax, which contains Sildenafil, is administered according to two distinct protocols based on the indication: intermittent use for Erectile Dysfunction (ED) or chronic use for Pulmonary Arterial Hypertension (PAH). The primary administration route is oral, typically using a film-coated tablet or an oral suspension, which is to be swallowed whole with water. For PAH, an intravenous (IV) form is also utilized for temporary hospital administration.


Dosing Patterns

Indication Dosing Schedule Frequency Pattern Key Timing Constraint
Erectile Dysfunction Starting dose is 50 mg, ranging from 25 mg to 100 mg. As-needed, or intermittent use. No more than once every 24 hours; taken approximately one hour prior to activity.
Pulmonary Arterial Hypertension Starting dose is typically 20 mg, ranging up to 80 mg per dose. Fixed-interval, or three times daily (TID). Taken at regular 8-hour intervals, with or without food.

Population-Specific Use and Administration

Clinical guidelines stipulate that certain patients may require a lower starting dose, typically 25 mg for ED, under medical supervision. This includes older adults (aged 65 years and over) and patients with severe hepatic or renal impairment due to altered drug clearance.

For the ED regimen, administration with a high-fat meal may delay the onset of the effect. For the chronic PAH regimen, if a fixed dose is missed, patients should take the next dose as soon as possible and resume the standard schedule, without taking two doses simultaneously. These procedures define the standardized approach to using the medicine.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Maxifort-Zimax


Evidence for Use in Erectile Dysfunction (ED)

The core research for Maxifort-Zimax (Sildenafil) in adult men with Erectile Dysfunction primarily involves short-term, randomized, controlled clinical trials (RCTs), complemented by systematic reviews. These studies were designed to explore how the compound compares to an inactive substitute, known as a placebo, over short time intervals, often a few weeks to several months. Researchers used patient-reported outcomes to assess changes in daily functioning.

Randomized studies reported observations where patients receiving the active compound described positive changes in measured outcomes compared to those receiving the placebo. Research describes changes measured during the study period, which were typically short-term observations, focusing on the acute response. Research is still exploring the long-term functional outcomes and maintenance of response over many years. The core efficacy data often applies specifically to a study design focused on single-dose response rather than continuous therapy.


Evidence for Use in Pulmonary Arterial Hypertension (PAH)

The evidence investigated for Sildenafil in Pulmonary Arterial Hypertension (PAH) comes from a different set of randomized, controlled trials (RCTs) designed for intermediate-term follow-up, typically lasting 12 to 16 weeks. These studies were established to examine measurements related to functional limitations associated with the condition. Key research monitored objective activity level measurements, such as the 6-Minute Walk Distance (6MWD), and tracking changes in the patient's assigned WHO Functional Class.

These trials reported measurements of change in the 6MWD, where observed patterns included the distance walked being greater in the group receiving Sildenafil relative to the placebo group after the intermediate follow-up period. Research describes observations related to certain physiological parameters, such as pulmonary pressures, which were monitored to assess systemic or functional imbalance.


What Remains Uncertain in the Research Record

The evidence highlights what is known—and what is still uncertain—about Maxifort-Zimax. A key limitation across both conditions is the difference between the study observation periods and the typically chronic nature of the conditions treated. Data quality varies across studies, and comparative evidence against certain other therapeutic options may be lacking. Long-term effects are not fully established in terms of life-long prognosis. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Label: SILDENAFIL tablet (DailyMed / FDA Monograph) - Relevant to general efficacy and safety profile.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Maxifort-Zimax (FAQ)


Q: How quickly does Maxifort-Zimax typically begin to work after the first use?

According to official product information, the active ingredient typically reaches its highest concentration in the blood within 30 to 120 minutes of being taken when a person is fasting. The onset of action for the treatment of Erectile Dysfunction is generally described as occurring approximately one hour after administration.


Q: Is it common for people to feel nauseous when starting Maxifort-Zimax?

Official regulatory documents list 'Dyspepsia' as a common side effect, which is a medical term for indigestion or upset stomach. This indicates that related feelings, such as stomach upset, are commonly reported. Nausea itself is not listed as frequently as dyspepsia in the primary adverse reaction tables.


Q: Are there known interactions between Maxifort-Zimax and herbal supplements?

Regulatory documents do not specifically list every herbal supplement. However, because Maxifort-Zimax is cleared by a specific liver enzyme (CYP3A4), any supplement known to affect this enzyme may potentially alter the drug’s concentration in the body. General patient information notes that a person should inform their healthcare provider about all supplements being taken.


Q: What kinds of medical supervision are generally described for people using Maxifort-Zimax?

Medical supervision is required for the initial prescription and for any necessary dosage changes. Monitoring is particularly noted when the drug is used by individuals with certain cardiovascular risk factors or those taking other blood-pressure lowering medications. This supervision is intended to monitor for potential issues like symptomatic hypotension (a noticeable drop in blood pressure).


Q: Does taking Maxifort-Zimax with food change how well it is absorbed?

Official pharmacokinetic studies indicate that the rate of absorption is reduced when Maxifort-Zimax is taken with a high-fat meal. This slows down the time it takes for the drug to reach its maximum concentration in the blood. While the drug is generally approved for use regardless of meals, the onset of its effect may be delayed with fatty foods.


Q: Do people take Maxifort-Zimax for reasons other than the main approved use?

Maxifort-Zimax is officially approved by regulatory agencies for the specific treatment of Erectile Dysfunction and Pulmonary Arterial Hypertension. Regulatory policy only provides guidelines and approved labeling for these indicated uses and does not endorse or provide information for uses not listed in the official approved documents.


Q: Is Maxifort-Zimax considered a long-term treatment or a short-term one?

The classification depends on the approved condition. For Erectile Dysfunction, the approved use is short-term and intermittent (as-needed). For Pulmonary Arterial Hypertension, the regimen requires fixed intervals and is considered a chronic treatment, often studied over intermediate-term periods, such as 12 to 16 weeks.


Q: What happens if a person forgets to use Maxifort-Zimax as scheduled?

For the chronic treatment of Pulmonary Arterial Hypertension, official administration procedures describe that a missed chronic dose may be taken when remembered, unless it is close to the time for the next dose. Regulatory guidelines specify that two doses should not be taken together to compensate for a missed one. The regimen for Erectile Dysfunction is taken only as needed, so there is no fixed schedule to miss.


Q: How long after stopping Maxifort-Zimax might the effects wear off?

The terminal half-life for the active ingredient is approximately four hours. This measurement describes the time it takes for the amount of the compound in the body to decrease by half. Due to this natural elimination process, the medication is considered to be mostly cleared from the body after several half-lives.


Q: Why might a doctor switch a patient from another drug to Maxifort-Zimax?

Regulatory documents describe the clinical evidence used for the drug's approval, such as positive changes in patient-reported outcomes for Erectile Dysfunction or objective changes in functional capacity for Pulmonary Arterial Hypertension. These documented findings, observed in study groups compared to placebo, are the basis for treatment assessments.


Q: Do older adults react differently to Maxifort-Zimax compared to younger adults?

Yes, regulatory pharmacokinetic studies indicate that older adults (aged 65 or over) often have higher concentrations of the active compound in their blood compared to younger adults. The difference in how the body processes the medication is consistent with regulatory instructions noting a need for a lower starting dose for older patients for the Erectile Dysfunction indication.


Q: Is Maxifort-Zimax known to affect a person's ability to drive or operate machinery?

Official regulatory warnings note that side effects such as dizziness and visual disturbances have been reported. Official patient information describes that patients should understand how the medication affects them before driving or operating machinery.


Q: Are changes in mood or sleep known side effects of Maxifort-Zimax?

Official safety documents for the active ingredient list difficulty sleeping (insomnia) as a potential side effect. Changes in mood are not listed among the frequently or very frequently reported adverse reactions.


Q: How long does the main ingredient in Maxifort-Zimax stay in the body?

The terminal half-life of the active ingredient and its major active metabolite is approximately four hours. This property is a key part of the compound's pharmacokinetics, describing the rate at which the body naturally eliminates the substance.


Q: What is the risk classification of Maxifort-Zimax during pregnancy or breastfeeding?

Regulatory documents state that Maxifort-Zimax is not indicated for women being treated for Erectile Dysfunction. When used for Pulmonary Arterial Hypertension, safety data in these populations is limited. Any use during pregnancy or while breastfeeding is reserved for situations where a healthcare provider assesses that the potential benefits outweigh the potential risks, due to the limited safety data in these populations.


Q: Are there official registry studies or follow-up data available for Maxifort-Zimax users?

The core evidence for the drug's effectiveness comes from short to intermediate-term clinical trials. However, some serious but rare adverse reactions, such as priapism or sudden vision loss, are documented through post-marketing surveillance, which confirms that data collection continues after the initial regulatory approval.


Q: Why is Maxifort-Zimax sometimes confused with treatments that do not contain its active ingredient?

Confusion can arise because the active ingredient (Sildenafil) is marketed under different brand names (e.g., Viagra and Revatio) for two separate medical conditions (Erectile Dysfunction and Pulmonary Arterial Hypertension). This difference in branding for the same molecule can be a source of confusion for patients.


Q: What is the process that regulatory agencies use to approve Maxifort-Zimax?

Regulatory bodies like the FDA and EMA use standardized, multi-step review processes to evaluate a drug. These processes require manufacturers to submit extensive data from clinical trials to establish that the drug meets defined standards for quality, safety, and effectiveness before approval is granted for specific uses.


Q: Are there any specific lifestyle restrictions described when using Maxifort-Zimax?

Regulatory instructions mention specific consumption restrictions, noting that high-fat meals may delay the onset of action and that alcohol intake is noted in regulatory sections. Beyond these consumption notes and specific medical contraindications, official documents do not impose general lifestyle restrictions on common daily activities.


Q: Why is consistency in using Maxifort-Zimax often mentioned as important?

The need for consistency is due to the treatment of Pulmonary Arterial Hypertension (PAH), which requires administration at fixed, regular intervals (e.g., every eight hours). This is necessary to maintain a consistent therapeutic level of the compound in the blood. Consistency is not required for the Erectile Dysfunction regimen, which is taken only as needed.


Q: Can Maxifort-Zimax cause stomach discomfort?

Official product information lists 'Dyspepsia' as a common side effect, which is a medical term for indigestion. This effect, which can manifest as upper stomach discomfort, is noted in safety documents as being observed in at least 1 in 100 users.


Q: Can Maxifort-Zimax cause problems with sun exposure or skin sensitivity?

Official safety documents list 'Rash' and 'Hypersensitivity reactions' as potential, less common adverse reactions. However, photosensitivity (a heightened sensitivity to sunlight) is not specifically listed among the commonly or very commonly reported side effects in the official adverse event tables.


Q: Does Maxifort-Zimax have a high potential for drug-drug interactions?

Yes, official documents describe several serious interactions. These include absolute prohibitions with certain compounds like organic nitrates, and also significant interactions with potent CYP3A4 inhibitors that necessitate mandatory dosing and timing restrictions to avoid excessively high concentrations of the drug in the body.


Q: Is it possible for the effects of Maxifort-Zimax to lessen over time (tolerance)?

While the core clinical trials for Erectile Dysfunction were short-term, some open-label extension studies tracking use for up to three years reported that patient satisfaction with the treatment's effect was generally maintained. Official adverse event tables do not list loss of response over time as a commonly or very commonly reported effect.


Q: How is Maxifort-Zimax different from the treatment options used before it was available?

Historically, Maxifort-Zimax (Sildenafil) was the first orally administered, FDA-approved treatment that worked by specifically inhibiting the PDE5 enzyme. Its approval marked a shift in the treatment of Erectile Dysfunction, offering a non-invasive, more convenient option compared to previous methods.

Advertisements

How should Maxifort-Zimax be stored and disposed of?

How to Store and Dispose of Maxifort-Zimax

Official regulatory documents define specific storage and disposal requirements for Sildenafil tablets (Maxifort-Zimax) to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Protection Keep the medication in the original container, tightly closed, and protect it from moisture.
Safety Keep the tablets strictly out of the reach of children.
Stability Do not use the product past the expiration date printed on the container.

Disposal Instructions

Unused or expired Maxifort-Zimax should be disposed of via a drug take-back program or an authorized mail-back envelope, as this is the preferred method. If these options are unavailable, the medication should be mixed with an undesirable substance (such as dirt) and sealed in a bag before being placed in the household trash. It must not be flushed down the toilet or placed in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Maxifort-Zimax found in:

A-Z Index: